- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01954290
Study of Stroke Related Edema Treatments
Treatment of Brain Edema and Herniation Secondary to Ischemic or Hemorrhagic Stroke
Stroke remains the fourth leading cause of death in the United States (second worldwide) and a leading cause of long-term disability, resulting in total direct and indirect costs of approximately $73.7 billion annually. The failure of novel therapies in clinical trials demonstrates that the complex neural response to stroke must be targeted at multiple levels to improve patient outcomes. Despite significant improvements in stroke treatment and management, 1 year survival rate among stroke patients aged 65 years or more is around 25%, and 5- year survival rate amounts to approximately 50%. The highest chances of death are within 30 days of stroke. Mortality increases due to worsening brain dysfunction, elevated intracranial pressure (ICP), and other comorbid conditions.
Treatments aimed at reducing post-stroke cytotoxic edema may reduce the risk for development of malignant stroke and mortality. Current treatments such as osmo-therapy and hemicraniectomy have substantial limitations, and mortality remains high, despite these measures outcomes remain unsatisfactory. There is a great need for alternative medical approaches which are safe, predictable, and help to ameliorate post stroke edema.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Previous work has demonstrated the pathophysiological role of arginine-vasopressin (AVP) in ischemic stroke. The mechanism of action of AVP is by 3 receptor subtypes: V1a, V1b and V2 expressed in brain, pituitary gland, myocardium, vasculature and kidneys. The role of the vasopressin receptors V1a and or V2 subtype in cerebral edema formation after ischemic stroke remains controversial. The V1a receptor antagonism causes platelet inhibition, aquaporin-4 up regulation; reduce infarct size and vasodilation. V1 antagonists has also been shown to prevent ischemia-induced cerebral edema development, suggesting that the V1 vasopressin receptor is important in water regulation in brain cells. Another study indicated that the vasopressin receptor V1 is involved in the pathogenesis of secondary brain damage after focal cerebral ischemia. Recently, few studies have demonstrated that a V2 receptor antagonist (OPC-31260), may be one of the effective drugs for the early treatment of cytotoxic edema and brain injury. Treatment of OPC-31260 ameliorated cerebral neurological deficit in transgenic (GET-1) mice after water intoxication. Treatment of OPC-31260 also significantly abolished water accumulation and down regulated Aquaporin-4 (AQP-4) expression level in GET-1 mice after water intoxication. The intensity of AQP-4 staining was almost comparable with that of the controls without water intoxication. It was also shown that OPC-31260 at doses of 10 to 30 mg/kg produced a dose-dependent inhibition of subarachnoid hemorrhage-induced cerebral edema formation, accompanied by an increase in urinary volume and decrease in urine osmolality without a significant alteration of urine electrolytes. OPC-31260 is also effective in treating water retention diseases, such as hyponatremia caused by inappropriate antidiuretic hormone secretion, congestive heart failure, and liver cirrhosis. V2 receptor antagonism will also help in abolishing water accumulation, decreased Glial Fibrillary Acidic Protein (GFAP) in astrocytes and most importantly causes renal tubule-selective diuretic effect called aquaresis (electrolyte sparing diuresis), which may have additional benefit in the reduction of cerebral edema.
This combined approach of V1a and V2 AVP receptor antagonism will lead to attenuation of ischemia related cerebral edema and infarct volume by modulating ischemia-evoked AQP-4 expression. This effect should help behavior and mortality which in turn will improve outcome in stroke patients. The purpose of this project is to test the effect of the mixed V1a and V2 receptor blockade on ischemic or hemorrhagic stroke outcome.
In summary, the investigators are using the approach of mixed vasopressin antagonism on post stroke edema, infarct volume and outcome. This research will lead to a greater understanding of the roles and interactions of the different AVP receptors and pathophysiology of post stroke cytotoxic edema. New information on the effects of mixed blockade of V1a and V2 receptors on the prevention of cytotoxic edema post stroke will be revealed.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with age ≥18 years and ≤80 years at the time of screening.
- Hemorrhagic stroke or large vessel ischemic stroke patients diagnosed by MRI or CT scan of Head.
- Subjects who have presented to hospital within 24 hours of symptom onset.
- The subject or his/ her legal representative is willing to undergo informed consent process prior to enrollment into this study.
Exclusion Criteria:
- Subject with age < 18 years and >80 years at the time of screening.
- Subjects with absence of stroke by imaging of brain by CT scan or MRI.
- Lacunar stroke or small vessel stroke.
- Time of symptom onset cannot be determined.
- Subjects with renal or hepatic failure.
- Subjects with hypovolemia or hypotension as determined by the study team.
- Subjects with hypernatremia.
- Subject who is pregnant or lactating.
- Subject is already participating in other investigational clinical trial.
- The subject or legal representative is unable to provide informed consent.
- The subject is medically unstable to participate in the trial as determined by the principal investigator.
- The subject has any end stage medical condition as determined by the principal investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Hypertonic Saline (3%) and/or Mannitol arm
The subjects in this arm will be given hypertonic saline and/or Mannitol. For hypertonic saline,various concentrations are used clinically,up to 30-mL boluses of 23.4% saline.Rapid increases in sodium in this context do not appear to cause other neurologic complications observed with rapid correction of hyponatremia.Sodium levels up to 160 mmol/L may be acceptable,beyond which it may lead to worsening delirium,seizures,and overall poor outcome. For Mannitol,every 4 hours serum osmolarity,serum glucose,urea,sodium and potassium will be measured till the therapy is given.Major complications include hypovolemia and hypotension.Strict fluid goals and volume replacement are essential.Impaired mannitol clearance may manifest as nephrotoxicity.Common practice includes repeating measurements of serum osmolarity and withholding repeat doses of mannitol when osmolarity exceeds 320 milliosmol(mOsm).Monitoring the osmole gap may be a more sensitive method for discerning mannitol clearance. |
Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium.
Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
Other Names:
Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes.
Maximum effect is seen in 20 minutes and duration of action is 4 hours.
Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
Other Names:
|
Experimental: Conivaptan arm
The subjects in this arm will be given infusion of Conivaptan.
|
Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Rankin Score
Time Frame: At the time of discharge from hospital, and 3 months after initial event
|
The modified Rankin Scale (m-RS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people after they have suffered a stroke.It is one of the most widely used clinical outcome measure for stroke clinical trials. The score is given according to following scale. 0- No symptoms at all
|
At the time of discharge from hospital, and 3 months after initial event
|
National Institutes of Health Stroke Severity (NIHSS) scale
Time Frame: At the time of discharge from hospital, and 3 months after initial event
|
NIHSS is a tool used by healthcare providers to objectively quantify the degree of impairment caused by a stroke.
It is composed of 11 items.
Each item scores a specific ability between a score of 0-4.
Usually, for each item, a score of 0 indicates normal function in that specific ability, while a higher score indicates some level of impairment.
The individual scores from each item are added together to calculate a patient's total NIHSS score.
The maximum possible score is 42, with the minimum score being a 0.
|
At the time of discharge from hospital, and 3 months after initial event
|
Neurological status of the subject
Time Frame: At the time of discharge from hospital, and 3 months after discharge
|
Neurological status of a stroke subject is assessed by physical neurological examination of the subject by a qualified neurologist.
It is one of the most important aspect in determining neurological health of a subject after treatment for stroke.
It also helps to determine stroke severity and prognosis.
|
At the time of discharge from hospital, and 3 months after discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All cause mortality data
Time Frame: 3 months after initial event
|
Mortality data indicates the severity of stroke.
|
3 months after initial event
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI brain- findings
Time Frame: 3 Months after Initial Event
|
MRI of the Brain.
|
3 Months after Initial Event
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vishnumurthy Shushuthra Hedna, MD, University of Florida
- Study Director: Michael F Waters, MD, University of Florida
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Stroke
- Edema
- Brain Edema
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Natriuretic Agents
- Diuretics, Osmotic
- Diuretics
- Antidiuretic Hormone Receptor Antagonists
- Mannitol
- Conivaptan
Other Study ID Numbers
- 136-2013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Edema
-
University Hospitals Coventry and Warwickshire...SuspendedHigh Altitude Cerebral EdemaUnited Kingdom
-
B.P. Koirala Institute of Health SciencesRecruitingAcute Mountain Sickness | High Altitude Cerebral Edema | High Altitude Pulmonary EdemaNepal
-
Goethe UniversityUnknownAcute Mountain Sickness | High Altitude Cerebral Edema | High Altitude Pulmonary EdemaGermany
-
Xuanwu Hospital, BeijingRecruiting
-
University Hospital, GrenobleUnknownAcute Mountain Sickness | High Altitude Cerebral Edema | High Altitude Pulmonary Edema
-
Minia UniversityUnknownDiffuse Traumatic Cerebral EdemaEgypt
-
Jesse CorryCompletedStroke | Cerebral Hemorrhage | Intracerebral Hemorrhage | Cerebral EdemaUnited States
-
Stanford UniversityWithdrawnCerebral Edema | Saline Solution, HypertonicUnited States
-
Jieshi MaCompletedHealthy | Cerebral Hemorrhage | Cerebral Edema | Cerebral IschemiaChina
-
The Second Hospital of Hebei Medical UniversityUnknownCerebral Infarction | Cerebral EdemaChina
Clinical Trials on Hypertonic saline
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)RecruitingModerate to Severe AsthmaUnited States
-
Western States Endurance Run Research FoundationUnknownExercise-associated HyponatremiaUnited States
-
Regional Hospital HolstebroCompleted
-
Aalborg UniversityRecruiting
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Cairo UniversityCompletedOptic Nerve Sheath | Hypertonic SalineEgypt
-
Dr. Michael FlavinWithdrawn
-
Szpital im. Św. Jadwigi ŚląskiejRecruiting